Resistance to antibiotics is the major cause of the failure to eradicate Helicobacter pylori. For such cases, alternative regimens need to be developed.
Perri et al. have reported an unacceptable low eradication rate of only 68% with a 7-day regimen of levofloxacin (LVX), amoxicillin (AMX), and pantoprazole (12) . However, Sharara et al. have recently reported an excellent eradication rate of 92% with a 7-day regimen of gatifloxacin (GAT), AMX, and rabeprazole (14) . It is important to note the superior in vitro activity of GAT over that of LVX against H. pylori (1). Therefore, GAT-based triple therapy might be a promising option for an alternative treatment regimen.
Several studies have shown that the "quinolone resistancedetermining region" (QRDR) of the gyrA gene plays a critical role in the resistance of H. pylori to ciprofloxacin (CIP) (8, 15) . H. pylori does not contain genes for topoisomerase IV, an important fluoroquinolone target in other bacteria (15) . The present study demonstrated a correlation between MICs to GAT and mutations of the gyrA and gyrB genes in H. pylori isolated from Japanese patients after unsuccessful eradication of infection.
A The susceptibility of H. pylori isolates to CRL, GAT, and MNZ was determined by the agar dilution method according to the guidelines established by the CLSI (formerly NCCLS) (9) . Isolates were considered resistant to MNZ if the MIC of the drug was Ն8 g/ml and resistant to CLR and GAT if the MIC of these drugs was Ն1 g/ml (3, 7, 10) . The resistance rates to GAT, CLR, and MNZ were 47.9%, 79.2%, and 6.3%, respectively. The GAT resistance rates were 22.2% (2/9) in the strains susceptible to both CLR and MNZ, 50% (18/36) in the strains resistant to CLR but susceptible to MNZ, 100% (1/1) in the strains resistant to MNZ but susceptible to CLR, and 100% (2/2) in the strains resistant to both CLR and MNZ.
Studies in Europe have suggested that the primary resistance rate might be as low as 8% for CIP (2, 16) and that only 9% of the isolates show resistance to CIP after failure of primary eradication (4, 13) . In contrast, our drug susceptibility tests showed a high resistance rate to GAT. Therefore, quinoloneresistant strains may be more prevalent in Japan than in Europe, due to wider use of fluoroquinolones.
We amplified by PCR and sequenced the QRDRs of gyrA (from codon 38 to 154) and gyrB (from codon 392 to 500) genes: gyrA (forward), 5Ј-TTTRGCTTATTCMATGAGCGT-3Ј; gyrA (reverse), 5Ј-GCAGACGGCTTGGTARAATA-3Ј; gyrB (forward), 5Ј-YGCAAAAGCCAGAGAAGCCA-3Ј; and gyrB (reverse), 5Ј-A CATGCCCTTGTTCAATCAGC-3Ј). The sequences obtained were compared with the published sequences of the H. pylori gyrA and gyrB genes (GenBank accession no. L29481) (3). Twenty-two of the 23 (95.7%) GAT-resistant strains had point mutations in the gyrA gene at codon 87 Asn or 91 Asp. On the other hand, only 1 of the 25 (4.0%) susceptible strains had the mutation, with a substitution at amino acid 87 (Tables 1 and 2 ). The sensitivity and specificity of detection of mutations in the gyrA gene in the GATresistant strains were 95.7% and 95.7%, respectively. Significant association was observed between mutations in the gyrA gene and resistance of the strains to GAT (P Ͻ 0.001). Mutations of the gyrB gene, on the other hand, were not encountered in either the susceptible or the resistant strains. The examination of mutations in the gyrA gene may be useful as a marker of GAT resistance.
Although many isolates bear the same gyrA mutation, their GAT MICs vary over an eightfold range. It might be due to the other mechanisms determining GAT MICs, such as an active multidrug efflux mechanism (5). Since the CmeABC efflux pump is linked to the acquired fluoroquinolone resistance in Campylobacter isolates (6), active efflux systems may also be involved in H. pylori susceptibility to GAT.
Four GAT-and CLR-susceptible strains were serially plated onto GAT (0.12 g/ml)-or CLR (0.015 g/ml)-containing agar with increasing agar density. Although none of the strains plated on CLR-containing agar developed resistance to GAT until the 10th generation of repeated culture, all four strains plated on GAT-containing agar developed GAT resistance and three strains showed mutations of gyrA, suggesting that a high incidence of GAT resistance could not arise through mutation of susceptible bacteria during the course of therapy with CLR, AMX, and PPI and could be due to primary infection with resistant bacteria or to history of fluoroquinolone treatment.
Oram and Fisher reported that examination of silent nucleotide changes in the gyrA genes revealed four different patterns of DNA polymorphism in Escherichia coli (11) . In the present study, compared with the reported sequence (GenBank accession no. L29481), there were C3T substitutions at position 108, 132, 210, 396, and 438, G3A substitutions at positions 276, 277, 291, and 318, T3C substitutions at positions 183 and 225, and A3G substitutions at positions 135 and 366. While KS0149 and KS0150 shared the same patterns of polymorphism, the other strains showed different patterns, indicating that these strains were not genetically related and that each strain developed GAT resistance during the previous fluoroquinolone usage.
In conclusion, a high resistance rate to GAT in H. pylori strains from Japanese patients is observed after unsuccessful eradication. Mutation in the gyrA gene of H. pylori was significantly associated with MICs for GAT equal to or above 1 g/ml. Although GAT may be one of the promising candidates for third-line therapy, the choice of GAT should be made after drug susceptibility tests or gyrA gene analysis.
